drugset / Trial / NCT02177773
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
Phase 1/2
Terminated
300 enrolled
University of California, San Francisco
Peterson Family Foundation · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This phase I/II trial studies how well gallium Ga 68-DOTA-TOC positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) works in imaging patients with somatostatin receptor positive tumors. Gallium Ga 68-DOTA-TOC binds to somatostatin receptor positive tumors and can be seen using a PET scan. A PET scan uses a special camera to detect energy given off from gallium Ga 68-DOTA-TOC, to make detailed pictures of areas where material accumulates in the body. Diagnostic procedures, such as gallium Ga 68-DOTA-TOC PET/CT or PET/MRI, may help find and diagnose somatostatin receptor positive tumors and help plan the best treatment.
Timeline
- Start
- 2014-06-23
- Primary completion
- 2017-08-07
- Completion
- 2017-08-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-DOTATOC | Peptide | — | Intravenous |